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impact of aldosterone antagonism on cardiac
structure and function in diabetic
cardiomyopathy
Melissa Leung1,3*, Vincent W Wong2,3,5, Stephane Heritier4, Anastasia S Mihailidou5 and Dominic Y Leung1,3Abstract: Development of a cardiomyopathy in diabetes mellitus is independent of traditional risk factors, with no
clinical trials targeting specific therapeutic interventions. Myocardial fibrosis is one of the key mechanisms and
aldosterone is a key mediator of myocardial fibrosis. We propose that aldosterone antagonism will improve cardiac
function. We aim to evaluate the efficacy of selective aldosterone receptor antagonism with eplerenone added to
optimal medical treatment in improving cardiac structure and function in diabetic cardiomyopathy. We will
randomize 130 patients with type 2 diabetes mellitus, stable metabolic control and impaired left ventricular (LV)
systolic or diastolic function, to either eplerenone (target dose 50mg) or matching placebo, in addition to optimal
medical therapy for 12 months. The primary endpoints are changes in LV systolic and diastolic function, measured
by echocardiographic 2-dimensional speckle tracking strain and strain rate and tissue Doppler imaging. The
secondary endpoints include changes in echocardiographic markers and plasma biomarkers of collagen turnover;
left atrial dimensions and function, incidence of atrial fibrillation and changes in exercise capacity and dyspnea
score. The present study will assess whether specific aldosterone antagonism with eplerenone in addition to
standard therapy will prevent progression or reverse cardiac dysfunction in diabetic cardiomyopathy using sensitive,
robust and quantifiable echocardiographic measures that allow early detection of change. The study may offer a
new direction in the management of this condition.
Trial registration: ACTRN12610001063000
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The incidence of obesity and type 2 diabetes mellitus
(T2DM) are increasing towards epidemic levels in both
developing and industrialized countries. Patients with
T2DM are at increased risk of heart failure from diabetic
cardiomyopathy [1], with the spectrum of disease ranging,
in early stages, from diastolic dysfunction to overt systolic
dysfunction during later stages. The pathogenesis of ven-
tricular dysfunction in diabetic cardiomyopathy is multi-
factorial, and independent of traditional cardiovascular
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reproduction in any medium, provided the orcoronary artery disease (CAD) (Figure 1) [2-5]. Patients
with heart failure and preserved ejection fraction, which
occurs in the early stages of diabetic cardiomyopathy, ex-
perience prognosis and functional decline similar to pa-
tients with heart failure and reduced ejection fraction.
Evidence based management guidelines are limited for
heart failure with preserved ejection fraction. Treatment is
mainly directed towards symptomatic relief with loop di-
uretics and treatment of associated conditions such as
hypertension. Definitive treatment to halt disease progres-
sion, improve prognosis and reverse the underlying patho-
physiology is still lacking.
Myocardial fibrosis has been suggested as one of the key
mechanisms underlying myocardial dysfunction in T2DM
[1]. Cardiac extracellular matrix (ECM) plays an active
role in modulating cardiac function and undergoesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Proposed scheme of development and progression of cardiac dysfunction as a result of the metabolic abnormalities seen in
diabetes. Legend: RAAS = renin–angiotensin II–aldosterone system, PPARs = peroxisome proliferator activator receptors, ER = endoplasmic
reticulum, ATP = adenosine triphosphate. From Mandavia CH, Aroor AR, DeMarco VG, Sowers JR: Molecular and metabolic mechanisms of cardiac
dysfunction in diabetes. Life sciences 2012, 92:601–608 [9]. Copyright 2012 by Elsevier Inc. Reprinted with permission.
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an injury-reparative process. Myocardial fibrosis involving
predominantly types I and III collagen, the most abundant
type in the heart, has been documented in biopsy studies
of diabetic patients without hypertension or CAD [6,7].
Furthermore, the synthesis of type III collagen has been
found to proportionally increase with hyperglycemia [8].
Overactivation of the renin angiotensin-II aldosterone
system (RAAS) occurs in diabetic cardiomyopathy
resulting in cardiac insulin resistance and a cascade of
abnormalities mediated by angiotensin II and aldoster-
one (Figure 1). Aldosterone plays an important role in
promoting fibrosis by stimulating fibroblast proliferation
and collagen synthesis, triggering proinflammatory fac-
tors leading to activation of matrix metalloproteinases
(MMPs), and increasing transforming growth factor-β
(TGF-β) [9]. Aldosterone antagonism has been shown to
improve symptoms and outcomes in advanced systolic
heart failure and after acute myocardial infarction
(AMI). Attenuation of the excessive ECM turnover by
aldosterone antagonism was suggested as one of the
mechanisms underlying its beneficial effects in systolic
heart failure [10,11]. The beneficial effects of aldosterone
antagonism on myocardial fibrosis may help to explain
the impressive improvement in patient outcomes in
systolic heart failure and after AMI despite only modest
improvement in left ventricular (LV) ejection fraction.Aldosterone antagonism with spironolactone adminis-
tered to patients with mildly symptomatic dilated cardio-
myopathy improved LV diastolic function and led to
regression in myocardial fibrosis on biopsy [12]. Similar
improvements in LV function and measures of fibrosis
have been documented in patients with hypertensive car-
diomyopathy [13] and metabolic syndrome [14]. How-
ever, the efficacy and safety of aldosterone antagonism
has not been previously evaluated in early stage diabetic
cardiomyopathy (ranging from isolated diastolic dysfunc-
tion to systolic dysfunction with NYHA functional class
I-II symptoms) where aldosterone antagonists are cur-
rently not indicated.
There is paucity of data on the specific use of aldoster-
one antagonists in T2DM and this is a particular group
who are prone to hyporeninemic hypoaldosteronism [15].
As a consequence, there are concerns regarding
hyperkalemia with the use of aldosterone antagonists, par-
ticularly in combination with angiotensin converting en-
zyme inhibitors (ACEI) or angiotensin receptor blockers
(ARB). Evaluation of this particular problem in clinical tri-
als has been limited to subgroup analyses. The present
study will provide safety information on the use of such
drugs in patients with T2DM.
Circulating biomarkers of collagen synthesis and degrad-
ation provide a means of monitoring ECM turnover and
the balance between collagen synthesis and degradation
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propeptide (PIIINP) and procollagen type I C-terminal
propeptide (PICP) have been shown to have prognostic
value in systolic heart failure [10,11], with aldosterone an-
tagonism decreasing levels of these biomarkers. Moreover,
clinical benefits were most predominant in those who had
elevated biomarker levels [11].
Cardiac imaging modalities such as echocardiography
and cardiac magnetic resonance imaging can be used to
quantify myocardial interstitial fibrosis. Histologically
quantified collagen accumulation has been shown to be
linearly related to the magnitude of ultrasound backscat-
ter, a marker of myocardial reflectivity, in experimental
[23,24] as well as in clinical studies [25,26]. The magni-
tude of integrated backscatter has been shown to correl-
ate with serum concentrations of PICP and PIIINP in
patients with hypertensive heart disease [27]. Diabetic
patients without hypertension, CAD, or overt heart
failure demonstrate evidence of systolic dysfunction and
abnormal calibrated integrated backscatter (IB). These
changes are not only similar to those caused by LV
hypertrophy, but are also independent and incremental
to the effects of ventricular hypertrophy [28]. The poten-
tial for assessing retardation or regression of this fibrosis
using ultrasound or biomarker surrogates in patients
with subclinical diabetic cardiomyopathy has not been
investigated. Furthermore, in contrast to the use of ejec-
tion fraction for assessing serial change in cardiac func-
tion, echocardiographic strain and strain rate imaging
provides a robust, sensitive, reproducible and quantifi-
able measure of changes in cardiac function that precede
changes in ejection fraction. Documentation of strain
and strain rate measures have the potential to allow earl-
ier detection of abnormalities as well as changes in car-
diac function to effect earlier intervention strategies
before the development of advanced heart disease.
The aim of the current study is to investigate whether
treatment with eplerenone, a specific aldosterone antag-
onist, for 12 months, in addition to ACEI or ARB, would
improve myocardial structural and functional abnormal-
ities in patients with diabetic cardiomyopathy without
advanced heart failure or severe LV systolic dysfunction.Research design and methods
This study was designed as a prospective, investigator-
initiated, multi-centre, randomized, double blind, placebo
controlled study to evaluate the impact of treatment with
eplerenone for 12 months on myocardial structure and
function in patients with T2DM and LV diastolic or sys-
tolic dysfunction, in the absence of class III-IV symptoms
with severe LV systolic dysfunction. The study was
conducted in accordance with the NHMRC guidelines
and was approved by Sydney Southwest Area HealthService Human Research Ethics committee. Figure 2
shows the study design and protocol.
Patients
Inclusion criteria
Eligible subjects include male and female adults that
meet the following criteria:
1) An established diagnosis of T2DM of any duration
and severity.
2) Presence of LV diastolic or systolic dysfunction.
3) Stable metabolic control (target blood pressure ≤135/
75 mmHg, lipids (total cholesterol ≤4.0 mmol/L,
LDL ≤ 2.0 mmol/L, TG ≤ 1.0 mmol/L), blood glucose
levels (HbA1c ≤ 8.0%)) such that minimal or no dose
changes of other medications, such as ACEI, ARB,
lipid lowering and blood glucose lowering medications
are anticipated during the course of the study.
4) NYHA functional class I or II.
5) Treatment with optimal target or maximal tolerated
dose of ACEI or ARB and ß-blocker, unless
contraindicated.
6) Serum potassium ≤5.0 mmol/L within 1 week prior
to randomization.
7) Estimated glomerular filtration rate (eGFR) > 30 ml/
min/1.73m2.
8) Subjects who received previous treatment with
aldosterone antagonists for more than 7 consecutive
days must meet the following additional criteria:
a. No history of clinically significant hyperkalemia
or renal impairment during previous aldosterone
antagonist treatment.
b. Aldosterone antagonist treatment has been
discontinued for at least 3 months prior to
randomization.Exclusion criteria
Subjects are not eligible for enrolment if they present
any of the following criteria:
1) Non-sinus rhythm.
2) Pregnancy.
3) Severe heart failure (class III-IV, LV ejection
fraction <35%).
4) Significant CAD (patients who have not undergone
recent coronary angiography will have significant
CAD excluded by stress echocardiography).
Further exclusion criteria pertain specifically to the
use of aldosterone antagonists, and include:
1) Serum potassium >5.0 mmol/L.
2) eGFR < 30 ml/min/1.73m2.
3) Concomitant potassium sparing diuretic.
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• Pregnancy
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Figure 2 Flow chart showing study design. Legend: TTE: transthoracic echo; LBBB: left bundle branch block; ACEI: angiotensin converting
enzyme inhibitors; ARB: angiotensin receptor blockers; 2D: 2 dimensional.
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5) Addison’s disease.
6) Acute renal insufficiency.
7) Severe hepatic insufficiency.
Screening and randomization
Preliminary screening for trial eligibility is based on
review of medical records by clinical trials staff at or
before the baseline visit. After written informed con-
sent, eligible subjects are randomly assigned by the
clinical trial pharmacist to treatment with eplerenone
or matching placebo. Randomization is by permuted
blocks and is conducted via an electronic data man-
agement system.
Echocardiography protocol
All patients will undergo resting echocardiography with
strain and strain rate imaging for evaluation of LV and
left atrial (LA) function. Myocardial calibrated IB will be
performed on grey scale 2-dimensional (2D) images to
assess the presence and extent of myocardial fibrosis.Two-dimensional and Doppler echocardiography
All transthoracic echocardiograms will be performed with
Vivid E9 (GE Medical Systems, Milwaukee, Wisconsin).
All standard echo and Doppler parameters of LV systolic
and diastolic function including tissue Doppler (TDI) will
be measured. Maximum, pre-P, and minimum LA vol-
umes will be measured using Simpson’s biplane method of
discs.
Strain and strain rate imaging
Longitudinal strain and strain rates of the left ventricle
(Figure 3) will be obtained using 2D speckle tracking.
Images of the left ventricle will be acquired in the apical
4-, 2-chamber and long axis views using highest possible
frame rates.
Left atrial longitudinal strain and strain rate will be
similarly obtained in 2 annular and 2 mid segments of
the apical 4- and 2-chamber views using velocity vector
imaging (VVI; syngo Velocity Vector Imaging technol-
ogy, Siemens Medical Solutions, Ultrasound Division,
Mountain View, California) (Figure 4). VVI will be used
Figure 3 Longitudinal strain and strain rate imaging by 2D speckle tracking for the apical 4-chamber view. The top panel is the strain
throughout one cardiac cycle for each of the color coded LV segments (mean strain shown by dotted white line). In this example, the mean peak
strain is about 27% which occurs during LV ejection, defined as the interval between aortic valve opening (AVO) and closure (AVC). The bottom
panel shows the corresponding LV strain rate. Note the negative strain rate in systole (S) and the positive strain rates (E during early diastole, and
A during late diastole).
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the LA wall, and the improved tracking with VVI com-
pared to 2D-speckle tracking for the left atrium.
Stress echocardiography
Stress echocardiography will be performed according to
standard protocols. Images will be acquired at rest and
peak exercise. Two-dimensional images of the left ven-
tricle will be obtained in the apical (4 chamber, 2 cham-
ber, long axis) and short axis (midventricular and apical)
views.
Calibrated integrated backscatter
The IB curves (Figure 5) will be extracted in the para-
sternal long-axis view, using standard software (Echopac,
GE Vingmed). Measurements will be obtained by placinga 9x9-pixel sample volume in the subendocardial basal
anteroseptum, posterior wall, and pericardium in end-
diastole in the parasternal long axis view. The position of
the sample volume will be checked and adjusted in each
frame to keep the sample volume within the same region
during the whole cardiac cycle. Calibrated IB is obtained
by subtracting average pericardial IB intensity from aver-
age myocardial IB intensity of the anteroseptum or poster-
ior wall.
Biomarker assays
Biomarker levels will be taken prior to commencement
of the study medication, as well as after 12 months treat-
ment. Peripheral venous blood will be obtained between
8am and 9am after 15 minutes of supine rest. Serum
P1NP and P3NP will be measured by radioimmunoassay
Figure 4 Velocity vector imaging for left atrial strain and strain rate in the apical 4-chamber (left images) and apical 2-chamber
(right images) views. The right lower image is an example of LA strain during atrial systole and the left lower image is an example of LA strain
rate curves. In the left lower image, the black line represents the global LA strain rate during LV systole, early and late diastole. The colored lines
represent the strain rates of the two annular and mid segments of the LA. The right lower image shows the global and segmental LA strain
during atrial systole (late ventricular diastole).
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measured by enzyme-linked immunoadsorbent assay
(Takara Bio, Shiga, Japan); plasma MMP-1 and MMP-9
will be measured by immunoassay (Millipore Corp, Mis-
souri, USA); plasma TIMP-1 levels will be measured by
enzyme-linked immunoadsorbent assay (RayBiotech Inc,
Georgia, USA); serum TGF-ß1 will be measured using
an enzyme-linked immunoadsorbent assay (R&D Sys-
tems, Minneapolis, Minnesota); and serum direct renin
and aldosterone levels will be quantified by radio-
immunoassay (Renin III Generation RIA kit, Cisbio Bio-
assays, Bagnols-Sur-Cèze, France; and Coat-A-Count
Aldosterone, Siemens Healthcare Diagnostics, Eschborn,
Germany; respectively). For quality control and valid-
ation purposes, all assays will be performed twice.
Functional tests
A 6-minute walk test will be performed and Medical Re-
search Council (MRC) dyspnea score recorded at
randomization and after 12 months of therapy.Dosing regimen
Eplerenone and placebo tablets and packaging are iden-
tical in appearance and are manufactured as 25mg tab-
lets by Pfizer (Pfizer, Inc, New York, USA). Subjects are
commenced on 25mg eplerenone or matching placebo
(1 × 25mg tablet) orally once daily, and may have their
dose up-titrated to 50mg (2 × 25mg tablet) after 4
weeks in the absence of worsening renal function or
hyperkalemia. In accordance with guidelines for man-
agement of heart failure [29,30], serum electrolytes and
renal function will be tested 1 and 4 weeks after dose
increase/commencement, then 3-monthly thereafter.
Study drug dose adjustment or dose maintenance is
guided by safety considerations, in particular changes
in serum potassium and renal function, which are mon-
itored at each visit. Patients will continue all other
usual medical treatments, whilst blood pressure, serum
cholesterol, hemoglobin A1c (HbA1c) and sugar diary
will be monitored at 3-monthly intervals to ensure on-
going optimal metabolic control. Blood pressure and
Figure 5 Assessment of left ventricular fibrosis by calibrated integrated backscatter (IB) in the parasternal long axis view. A 9 × 9 pixel
sample volume is placed in the mid-myocardium of the basal anteroseptum, posterior wall, and pericardium, and is tracked throughout the
cardiac cycle. In this example, calibrated IB for the anteroseptum is obtained by subtracting average pericardial IB intensity (−3.3 dB) from average
myocardial IB intensity of the septum (−19.2 dB), which results in a calibrated IB for the septum of −15.9 dB.
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a newly calibrated semiautomatic oscillometric device
with a digital readout (Omron T9, Omron Healthcare,
Melbourne, Australia). The subjects will be seated in a
quiet room and blood pressure measurements started
after a 10–15min rest period. Measurements will be
performed in the same arm each time and with a cuff
size appropriate to the patient’s arm. The cuff will be
kept at the heart level, and the arm will be supported at
the time of the measurement. Three measurements will
be made at least 15 seconds apart, and the averages
recorded. Visits will take place at the same time of the
day, usually in the morning, Treatment will be
maintained and monitored for 12 months, when repeat
cardiac imaging, functional testing and biomarker ana-
lysis will be performed.
Endpoints
The primary endpoints are changes in global mean peak
LV systolic strain and strain rate, peak early diastolic myo-
cardial tissue Doppler velocities at the basal septal LV wall
(e’), the ratio of mitral inflow early diastolic velocity to
peak early diastolic mitral annular velocity (E/e’), LV cali-
brated IB, LV mass index and LA strain and strain rate at
ventricular systole and early and late ventricular diastole,
and LA phasic volumes. Secondary endpoints include
changes in collagen turnover measured as changes in
serum levels of procollagen type I aminoterminal peptide
(PINP), PIIINP, PICP, matrix metalloproteinases 1 and 9
(MMP-1, MMP-9), tissue inhibitor of metalloproteinase-1
(TIMP-1), renin, and aldosterone levels). Other secondary
endpoint measurements include MRC dyspnea score,exercise tolerance, as measured by 6-minute walk test dis-
tance and incidence of atrial fibrillation.
Serious adverse events (SAE) including life-threatening
hyperkalemia (>7mmol/L), acute renal failure, hypotension
and death will be monitored.
Hypotheses
1. Aldosterone antagonism with eplerenone in diabetic
cardiomyopathy leads to an improvement in LV
systolic and diastolic function, measured by 2D
speckle tracking strain and strain rate imaging.
2. Myocardial fibrosis, as measured by
echocardiographic calibrated IB and serum collagen
biomarkers is reduced by eplerenone.
3. Eplerenone improves LA function and phasic
volumes.
4. Changes in LV and LA function with eplerenone are




At the time of study design and commencement, there
were no studies that examined the impact of aldosterone
antagonism with eplerenone on cardiac function as mea-
sured by strain and strain rate imaging and cardiac fibro-
sis in patients with diabetic cardiomyopathy. Therefore,
sample size calculation was based on previous studies that
examined the effects of spironolactone on strain and
strain rate in patients with diastolic heart failure from di-
lated and hypertensive cardiomyopathies, changes in
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ences in IB between patients with early diabetic cardiomy-
opathy and normal controls [12,13,28,31]. The change in
IB between baseline and 12 month echocardiograms will
be measured in both placebo and eplerenone arms (ΔIB).
A sample size of 65 patients per treatment group (130 pa-
tients in total) will achieve 80% power to detect a differ-
ence in ΔIB of −4.5 dB (SD = 7) with two-sided α = 0.05
using a two-sample t-test. This includes a 10% loss to
follow-up rate for clinic visits and repeat echocardiograms,
as well as a 15% non-compliance rate with eplerenone or
placebo. A power of at least 80% was also obtained for
peak longitudinal systolic strain and strain rate, and early
diastolic strain rate using similar calculations.
Since commencement of this study, Kosmala and col-
leagues [14] examined the effects of spironolactone ver-
sus placebo on cardiac function in patients with
metabolic syndrome and found improvements in longi-
tudinal strain and strain rate over a 6-month period, but
no significant difference in ΔIB. Sample size recalcu-
lation has shown that the intended sample size of 130
patients in the present study provides adequate power to
detect a difference over the 12 month time period in LV
strain and strain rate.
These sample size calculations are based on a two-
sample t-test and are therefore conservative. As analysis of
covariance (ANCOVA) adjusted for the baseline measure-
ment will be the method of analysis, the power will be
higher or the minimal detectable effect smaller for the
same power target. The gain in efficiency is linked to the
correlation (r) between the baseline and on-treatment
measurements which is currently unknown for the end-
points involved, but expected to be high [32].
Trial oversight
A data safety and monitoring board (DSMB) comprising
of personnel with sufficient cardiological, endocrino-
logical and statistical experience will be formed to re-
view the interim results and oversee the conduct of the
trial. The DSMB and ethics committee will review all
unblinded data on clinical endpoint events and deter-
mine whether events meet pre-specified criteria. The
DSMB will monitor safety and efficacy of the trial and
periodically assess whether the trial should continue.
Interim analysis
Interim analyses for safety and efficacy are incorporated
into this trial. The Haybittle-Peto rule with two interim ef-
ficacy analyses detailed in a statistical analysis plan are
planned after approximately 30% and 60% of the patients
have been followed up at 12 months. Early termination for
the study will be recommended for evidence of over-
whelming benefit (2-sided p < 0.003 favouring eplerenone)
or substantive harm (2-sided p < 0.01 against eplerenone).Statistical analysis
The intention-to-treat principle will be applied to the
analysis. Baseline and demographic characteristics will
also be summarized by treatment group. All changes
from baseline, including the primary and secondary end-
points will be analysed by means of ANCOVA, adjusted
for the baseline measurement.
Descriptive statistics will be provided for safety data.
The number of patients reporting any SAE, the occur-
rence of specific SAEs and discontinuation due to
SAEs will be tabulated. The effect of treatment on the
number of patients experiencing at least one SAE will
be tested using a χ2-test or Fisher’s exact test if the
number of events is small. All hypotheses are two-
sided. A p-value of <0.05 is considered statistically
significant.
Discussion
There are features of this trial design that deserve par-
ticular emphasis:
 Patients of all symptomatology and degrees of
myocardial abnormalities ranging from grade 1–3
diastolic dysfunction to mild to moderate systolic
dysfunction are enrolled. Including patients with
more severe grades of baseline diastolic or systolic
dysfunction may allow greater improvement on
eplerenone. Furthermore, patients with milder
degrees of systolic/diastolic dysfunction randomized
to placebo may experience disease progression
during the course of the study.
 Blood pressure independent effects of eplerenone
will be examined by recruiting those with stable
blood pressure control at baseline, and blood
pressure will be continually monitored to ensure
stability throughout the study. Furthermore, the
dose of eplerenone will not exceed 50mg daily,
minimizing the antihypertensive effects.
 The impact of aldosterone antagonism on
myocardial fibrosis will be measured both by cardiac
imaging and serum levels of biomarkers.
Furthermore, attempts will be made to correlate the
changes in myocardial function with changes in the
degree of myocardial fibrosis both on imaging as
well as changes in biomarker levels.
 In comparison to previous studies examining
biomarkers of fibrosis, it is assumed that the
beneficial effects of aldosterone antagonism come
from more effective suppression of aldosterone, yet
few have definitively shown that this beneficial effect
is present despite a persistently elevated renin and
aldosterone level after treatment. We will measure
both renin and aldosterone level before and after
treatment in our study.
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Diabetic cardiomyopathy is an increasingly prevalent
disorder for which there is currently no specific thera-
peutic intervention. This trial, when successfully
completed, will advance our understanding of diabetic
cardiomyopathy and the underlying mechanisms. This
may provide a new direction in the management of dia-
betes; the early treatment by eplerenone may prevent
and reverse the progression of atrial and ventricular dys-
function and myocardial fibrosis to irreversible structural
and symptomatic cardiac disease. Thus, the proposed re-
search will have a favourable impact in turning the focus
of treatment of this disease from secondary prevention
and heart failure symptom management into an interven-
tional approach at the preclinical stage. This may result in
a reduction in morbidity and mortality for patients with
T2DM, with improved outcomes and consequent substan-
tial health cost savings for the community.
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